CR Bard CE-marks Memotherm carotid stent:
This article was originally published in Clinica
CR Bard has CE-marked its nitinol Memotherm carotid stent. The device is designed to self expand once it is inserted and conform to the artery. The company believes this will help to contain the build-up of artheroscleroic plaque which can lead to a stroke. The stent's thermoelastic properties also prevent deformation which might be caused by external compression in the neck. Carotid artery disease is one of the major precursors to ischemic stroke in the US. According to Murray Hill, New Jersey-based Bard, carotid artery stenting provides a less invasive and less expensive way of treating this disease.
You may also be interested in...
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.